Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives

Front Med (Lausanne). 2021 Nov 30:8:738850. doi: 10.3389/fmed.2021.738850. eCollection 2021.

Abstract

Kawasaki disease (KD), an acute, generalized vasculitis, is associated with an increased risk of coronary heart disease and is the most common cause of acquired heart disease in childhood. The incidence of KD is increasing worldwide. There are numerous international treatment guidelines. Our study aims to perform the first one so far comparison of them. While the gold standard therapy remains still the same (intravenous immunoglobulins and aspirin), there is currently a lack of evidence for choosing optimal treatment for high-risk patients and refractory KD. In this review, we also discuss the treatment of complications of KD and Kawasaki-like phenotypes, present an anti-inflammatory treatment in the light of new scientific data, and present novel potential therapeutic targets for KD.

Keywords: Kawasaki disease; MIS-C; PIMS-TS; SARS-CoV-2; anti-inflammatory treatment; coronary artery aneurysm; guidelines; vasculitis.

Publication types

  • Review